TY - STD TI - van Dalen EC, Raphael MF, Caron HN, Kremer LCM. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer. Cochrane Database Syst Rev. 2014:CD006647. https://doi.org/10.1002/14651858.CD006647.pub4. ID - ref1 ER - TY - JOUR AU - Adams, M. J. AU - Lipshultz, S. E. PY - 2005 DA - 2005// TI - Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention JO - Pediatr Blood Cancer VL - 44 UR - https://doi.org/10.1002/pbc.20352 DO - 10.1002/pbc.20352 ID - Adams2005 ER - TY - JOUR AU - Lipshultz, S. E. AU - Colan, S. D. AU - Gelber, R. D. AU - Perez-Atayde, A. R. AU - Sallan, S. E. AU - Sanders, S. P. PY - 1991 DA - 1991// TI - Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood JO - N Engl J Med VL - 324 UR - https://doi.org/10.1056/NEJM199103213241205 DO - 10.1056/NEJM199103213241205 ID - Lipshultz1991 ER - TY - JOUR AU - Hoff, D. D. AU - Layard, M. W. AU - Basa, P. AU - Davis, H. L. AU - Hoff, A. L. AU - Rozencweig, M. PY - 1979 DA - 1979// TI - Risk factors for doxorubicin-induced congestive heart failure JO - Ann Intern Med VL - 91 UR - https://doi.org/10.7326/0003-4819-91-5-710 DO - 10.7326/0003-4819-91-5-710 ID - Hoff1979 ER - TY - JOUR AU - Swain, S. M. AU - Whaley, F. S. AU - Ewer, M. S. PY - 2003 DA - 2003// TI - Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials JO - Cancer. VL - 97 UR - https://doi.org/10.1002/cncr.11407 DO - 10.1002/cncr.11407 ID - Swain2003 ER - TY - STD TI - van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2011:CD003917. https://doi.org/10.1002/14651858.CD003917.pub4. ID - ref6 ER - TY - STD TI - van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2010:CD005006. https://doi.org/10.1002/14651858.CD005006.pub4. ID - ref7 ER - TY - JOUR AU - Bielack, S. S. AU - Erttmann, R. AU - Kempf-Bielack, B. AU - Winkler, K. PY - 1996 DA - 1996// TI - Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties? JO - Eur J Cancer VL - 32 UR - https://doi.org/10.1016/0959-8049(96)00177-3 DO - 10.1016/0959-8049(96)00177-3 ID - Bielack1996 ER - TY - JOUR AU - Robert, J. PY - 1987 DA - 1987// TI - Continuous infusion or intravenous bolus: what is the rationale for doxorubicin administration? JO - Cancer Drug Deliv VL - 4 UR - https://doi.org/10.1089/cdd.1987.4.191 DO - 10.1089/cdd.1987.4.191 ID - Robert1987 ER - TY - JOUR AU - Dalen, E. C. AU - Pal, H. J. H. AU - Kremer, L. C. M. PY - 2016 DA - 2016// TI - Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy JO - Cochrane Database Syst Rev VL - 3 UR - https://doi.org/10.1002/14651858.CD005008.pub4 DO - 10.1002/14651858.CD005008.pub4 ID - Dalen2016 ER - TY - JOUR AU - Steinherz, P. G. AU - Redner, A. AU - Steinherz, L. AU - Meyers, P. AU - Tan, C. AU - Heller, G. PY - 1993 DA - 1993// TI - Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse: the memorial Sloan-Kettering-New York-II protocol JO - Cancer. VL - 72 UR - https://doi.org/3.0.CO;2-Q DO - 3.0.CO;2-Q ID - Steinherz1993 ER - TY - JOUR AU - Escherich, G. AU - Göbel, U. AU - Jorch, N. AU - Spaar, H. J. AU - Janka-Schaub, G. E. PY - 2007 DA - 2007// TI - Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia JO - Klin Padiatr VL - 219 UR - https://doi.org/10.1055/s-2007-973849 DO - 10.1055/s-2007-973849 ID - Escherich2007 ER - TY - JOUR AU - Lipshultz, S. E. AU - Giantris, A. L. AU - Lipsitz, S. R. AU - Kimball Dalton, V. AU - Asselin, B. L. AU - Barr, R. D. PY - 2002 DA - 2002// TI - Doxorubicin administration by continuous infusion is not Cardioprotective: the Dana-Farber 91-01 acute lymphoblastic leukemia protocol JO - J Clin Oncol VL - 20 UR - https://doi.org/10.1200/JCO.2002.20.6.1677 DO - 10.1200/JCO.2002.20.6.1677 ID - Lipshultz2002 ER - TY - JOUR AU - Lipshultz, S. E. AU - Miller, T. L. AU - Lipsitz, S. R. AU - Neuberg, D. S. AU - Dahlberg, S. E. AU - Colan, S. D. PY - 2012 DA - 2012// TI - Continuous versus bolus infusion of doxorubicin in children with ALL: long-term cardiac outcomes JO - Pediatrics. VL - 130 UR - https://doi.org/10.1542/peds.2012-0727 DO - 10.1542/peds.2012-0727 ID - Lipshultz2012 ER - TY - JOUR AU - Völler, S. AU - Boos, J. AU - Krischke, M. AU - Würthwein, G. AU - Kontny, N. E. AU - Boddy, A. V. PY - 2015 DA - 2015// TI - Age-dependent pharmacokinetics of doxorubicin in children with cancer JO - Clin Pharmacokinet VL - 54 UR - https://doi.org/10.1007/s40262-015-0272-4 DO - 10.1007/s40262-015-0272-4 ID - Völler2015 ER - TY - JOUR AU - Völler, S. AU - Hempel, G. AU - Würthwein, G. AU - Boddy, A. V. AU - Krischke, M. AU - Andre, N. PY - 2017 DA - 2017// TI - Towards a model-based dose recommendation for doxorubicin in children JO - Clin Pharmacokinet VL - 56 UR - https://doi.org/10.1007/s40262-016-0451-y DO - 10.1007/s40262-016-0451-y ID - Völler2017 ER - TY - JOUR AU - Balis, F. r. a. n. k. M. AU - Womer, R. i. c. h. a. r. d. B. AU - Berg, S. t. a. c. e. y. AU - Winick, N. a. o. m. i. AU - Adamson, P. e. t. e. r. C. AU - Fox, E. l. i. z. a. b. e. t. h. PY - 2017 DA - 2017// TI - Dosing anticancer drugs in infants: Current approach and recommendations from the Children's Oncology Group's Chemotherapy Standardization Task Force JO - Pediatric Blood & Cancer VL - 64 UR - https://doi.org/10.1002/pbc.26636 DO - 10.1002/pbc.26636 ID - Balis2017 ER - TY - BOOK PY - 2010 DA - 2010// TI - Centers for Disease Control and Prevention growth charts ID - ref18 ER - TY - JOUR AU - Sheiner, L. B. AU - Beal, S. L. PY - 1981 DA - 1981// TI - Some suggestions for measuring predictive performance JO - J Pharmacokinet Biopharm VL - 9 UR - https://doi.org/10.1007/BF01060893 DO - 10.1007/BF01060893 ID - Sheiner1981 ER - TY - BOOK PY - 2010 DA - 2010// TI - Guideline on the investigation of bioequivalence ID - ref20 ER - TY - BOOK AU - Beal, S. AU - Sheiner, L. B. AU - Boeckmann, A. AU - Bauer, R. J. PY - 2009 DA - 2009// TI - NONMEM Users’s guides (1989–2009) PB - Icon Development Solutions CY - Ellicott City ID - Beal2009 ER - TY - BOOK PY - 2018 DA - 2018// TI - R: a language and environment for statistical computing PB - R Foundation for Statistical Computing CY - Vienna ID - ref22 ER - TY - BOOK PY - 2016 DA - 2016// TI - RStudio: integrated development environment for R PB - RStudio, Inc. CY - Boston ID - ref23 ER - TY - JOUR AU - Mertens, A. C. AU - Liu, Q. AU - Neglia, J. P. AU - Wasilewski, K. AU - Leisenring, W. AU - Armstrong, G. T. PY - 2008 DA - 2008// TI - Cause-specific late mortality among 5-year survivors of childhood cancer: the childhood cancer survivor study JO - J Natl Cancer Inst VL - 100 UR - https://doi.org/10.1093/jnci/djn310 DO - 10.1093/jnci/djn310 ID - Mertens2008 ER - TY - JOUR AU - Rössig, C. AU - Jürgens, H. AU - Schrappe, M. AU - Möricke, A. AU - Henze, G. AU - Stackelberg, A. PY - 2013 DA - 2013// TI - Effective childhood cancer treatment: the impact of large scale clinical trials in Germany and Austria JO - Pediatr Blood Cancer VL - 60 UR - https://doi.org/10.1002/pbc.24598 DO - 10.1002/pbc.24598 ID - Rössig2013 ER - TY - JOUR AU - Palle, J. AU - Frost, B. -. M. AU - Peterson, C. AU - Gustafsson, G. AU - Hellebostad, M. AU - Kanerva, J. PY - 2006 DA - 2006// TI - Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia JO - Anticancer Drugs VL - 17 UR - https://doi.org/10.1097/01.cad.0000198911.98442.16 DO - 10.1097/01.cad.0000198911.98442.16 ID - Palle2006 ER - TY - JOUR AU - Powell, C. PY - 2003 DA - 2003// TI - The Delphi technique: myths and realities JO - J Adv Nurs VL - 41 UR - https://doi.org/10.1046/j.1365-2648.2003.02537.x DO - 10.1046/j.1365-2648.2003.02537.x ID - Powell2003 ER - TY - JOUR AU - Jonge, M. E. AU - Huitema, A. D. R. AU - Schellens, J. H. M. AU - Rodenhuis, S. AU - Beijnen, J. H. PY - 2005 DA - 2005// TI - Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation a review JO - Clin Pharmacokinet VL - 44 UR - https://doi.org/10.2165/00003088-200544020-00002 DO - 10.2165/00003088-200544020-00002 ID - Jonge2005 ER - TY - JOUR AU - Thomas, H. AU - Boddy, A. V. AU - English, M. W. AU - Hobson, R. AU - Imeson, J. AU - Lewis, I. PY - 2000 DA - 2000// TI - Prospective validation of renal function–based carboplatin dosing in children with cancer: a United Kingdom Children’s cancer study group trial JO - J Clin Oncol VL - 18 UR - https://doi.org/10.1200/JCO.2000.18.21.3614 DO - 10.1200/JCO.2000.18.21.3614 ID - Thomas2000 ER - TY - JOUR AU - Loeffen, E. r. i. k. A. H. AU - van Dalen, E. l. v. i. r. a. C. AU - Mulder, R. e. n. é. e. L. AU - van de Wetering, M. a. r. i. a. n. n. e. D. AU - Kremer, L. e. o. n. t. i. e. n. C. M. AU - Tissing, W. i. m. J. E. PY - 2017 DA - 2017// TI - The duration of anthracycline infusion should be at least one hour in children with cancer: A clinical practice guideline JO - Pediatric Blood & Cancer VL - 65 UR - https://doi.org/10.1002/pbc.26867 DO - 10.1002/pbc.26867 ID - Loeffen2017 ER - TY - JOUR AU - Kremer, L. C. M. AU - Dalen, E. C. AU - Offringa, M. AU - Voûte, P. A. PY - 2002 DA - 2002// TI - Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review JO - Ann Oncol VL - 13 UR - https://doi.org/10.1093/annonc/mdf118 DO - 10.1093/annonc/mdf118 ID - Kremer2002 ER - TY - BOOK PY - 2007 DA - 2007// TI - Guideline on reporting the results of population pharmacokinetic analyses ID - ref32 ER - TY - STD TI - Akins RB, Tolson H, Cole BR. Stability of response characteristics of a Delphi panel: application of bootstrap data expansion. BMC Med Res Methodol. 2005. https://doi.org/10.1186/1471-2288-5-37. ID - ref33 ER - TY - JOUR AU - Jacquet, J. -. M. AU - Bressolle, F. AU - Galtier, M. AU - Bourrier, M. AU - Donadio, D. AU - Jourdan, J. PY - 1990 DA - 1990// TI - Doxorubicin and doxorubicinol: intra-and inter-individual variations of pharmacokinetic parameters JO - Cancer Chemother Pharmacol VL - 27 UR - https://doi.org/10.1007/BF00685716 DO - 10.1007/BF00685716 ID - Jacquet1990 ER - TY - JOUR AU - Eksborg, S. AU - Strandler, H. -. S. AU - Edsmyr, F. AU - Näslund, I. AU - Tahvanainen, P. PY - 1985 DA - 1985// TI - Pharmacokinetic study of IV infusions of Adriamycin JO - Eur J Clin Pharmacol VL - 28 UR - https://doi.org/10.1007/BF00609693 DO - 10.1007/BF00609693 ID - Eksborg1985 ER - TY - JOUR AU - Frost, B. -. M. AU - Eksborg, S. AU - Björk, O. AU - Abrahamsson, J. AU - Behrendtz, M. AU - Castor, A. PY - 2002 DA - 2002// TI - Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study JO - Med Pediatr Oncol VL - 38 UR - https://doi.org/10.1002/mpo.10052 DO - 10.1002/mpo.10052 ID - Frost2002 ER - TY - JOUR AU - Evans, W. E. AU - Relling, M. V. AU - Rodman, J. H. AU - Crom, W. R. AU - Boyett, J. M. AU - Pui, C. H. PY - 1998 DA - 1998// TI - Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia JO - N Engl J Med VL - 338 UR - https://doi.org/10.1056/NEJM199802193380803 DO - 10.1056/NEJM199802193380803 ID - Evans1998 ER - TY - JOUR AU - Gamelin, E. AU - Delva, R. AU - Jacob, J. AU - Merrouche, Y. AU - Raoul, J. L. AU - Pezet, D. PY - 2008 DA - 2008// TI - Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.13.3934 DO - 10.1200/JCO.2007.13.3934 ID - Gamelin2008 ER - TY - JOUR AU - Hempel, G. AU - Flege, S. AU - Würthwein, G. AU - Boos, J. PY - 2002 DA - 2002// TI - Peak plasma concentrations of doxorubicin in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma JO - Cancer Chemother Pharmacol VL - 49 UR - https://doi.org/10.1007/s00280-001-0392-4 DO - 10.1007/s00280-001-0392-4 ID - Hempel2002 ER - TY - JOUR AU - Kontny, N. E. AU - Wurthwein, G. AU - Joachim, B. AU - Boddy, A. V. AU - Krischke, M. AU - Fuhr, U. PY - 2013 DA - 2013// TI - Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years JO - Cancer Chemother Pharmacol VL - 71 UR - https://doi.org/10.1007/s00280-013-2069-1 DO - 10.1007/s00280-013-2069-1 ID - Kontny2013 ER - TY - JOUR AU - Bardin, C. AU - Veal, G. AU - Paci, A. AU - Chatelut, E. AU - Astier, A. AU - Levêque, D. PY - 2014 DA - 2014// TI - Therapeutic drug monitoring in cancer--are we missing a trick? JO - Eur J Cancer VL - 50 UR - https://doi.org/10.1016/j.ejca.2014.04.013 DO - 10.1016/j.ejca.2014.04.013 ID - Bardin2014 ER -